Company intelligence / Profile preview
CVI Pharmaceuticals (Shanghai) Co Ltd
Palo Alto, California, United Statescvipharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The lead program, CVI-LM001, is a first-in-class oral PCSK9 modulator with completed positive Phase 2 proof-of-concept trial in China for hypercholesterolemia; demonstrated robust reduction of LDL-C and liver fat, favorable safety and pharmacokinetics in clinical and preclinical studies
- Therapeutic areas
- CardiovascularGastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Exclusive China licensing agreement with Yangtze River Pharmaceuticals Group for CVI-LM001
Beyond the preview
Go deeper on CVI Pharmaceuticals (Shanghai) Co Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVI Pharmaceuticals (Shanghai) Co Ltd.